GO:0046696 lipopolysaccharide receptor complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046696 defines the lipopolysaccharide receptor complex, a glycosylated multiprotein assembly of CD14, TLR4, and MD-2 that senses bacterial LPS and primes innate immunity.
• The complex is not a static entity: its expression and composition are modulated in systemic inflammatory response syndrome and in infected macrophages, depending on LPS serotype and host state [1,5].
• TLR4 is the signal-transducing subunit; MD-2 is the direct LPS-binding co-receptor; CD14 concentrates LPS and presents it to the TLR4/MD-2 pair.
• Beyond canonical NF-kB activation, the complex intersects with non-canonical inflammasome pathways, including caspase-4 sensing of intracellular LPS.
• The complex is expressed by resident antigen-presenting cells in immune-privileged tissues such as the human uvea, and by tissue CD14+CD8+ T cells reprogrammed by myeloid cells [2,6].
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of each subunit in LPS responses and inflammatory disease [1,2,5].
Description
The lipopolysaccharide receptor complex (GO:0046696) is a cellular component defined by the Gene Ontology as a multiprotein complex consisting of at least three glycosylated proteins, CD14, TLR4, and MD-2, which together function as a receptor for lipopolysaccharide (LPS) and prime the innate immune response against bacterial pathogens. This complex is the first line of microbial recognition at the cell surface and is therefore central to inflammation, sepsis, and host defense [4,5]. Researchers study it because its subunit composition, glycosylation, and expression levels determine whether LPS triggers protective immunity or pathological cytokine storms [1,5]. The complex is not a single fixed stoichiometric unit; its components are dynamically regulated. In patients with systemic inflammatory response syndrome, expression of CD14, TLR4, and MD-2 is modulated and correlates with tolerance to LPS. In infected RAW264.7 macrophages, the gene expression of the lipopolysaccharide receptor complex is influenced by lysophosphatidylcholine acetyltransferase 2 (LPCAT2) and depends on the E. coli LPS serotype, showing that host lipid metabolism and microbial ligand structure both shape receptor output. Functionally, the complex bridges extracellular LPS recognition to intracellular signaling. TLR4 is the signaling subunit, MD-2 is the direct LPS-binding protein, and CD14 is a glycosylphosphatidylinositol-anchored or soluble co-receptor that transfers LPS to the TLR4/MD-2 pair. Downstream, the complex activates NF-kB and interferon regulatory factors, and it also intersects with inflammatory caspase-4, which cleaves cytokines and drives non-canonical inflammasome responses. This dual role makes GO:0046696 a high-value target for CRISPR-based functional genomics in immunology and infectious disease research [1,2,5].
lipopolysaccharide receptor complex At A Glance
| GO ID | GO:0046696 |
|---|---|
| GO term | lipopolysaccharide receptor complex |
| Ontology | cellular_component |
| Synonym | LPS receptor complex |
| Definition | A multiprotein complex that consists of at least three proteins, CD14, TLR4, and MD-2, each of which is glycosylated and which functions as a lipopolysaccharide (LPS) receptor that primes the innate immune response against bacterial pathogens. |
| Major function | Recognition of bacterial LPS and initiation of innate immune signaling. |
| Core subunits | CD14, TLR4, MD-2 (LY96). |
| Post-translational feature | All three core proteins are glycosylated. |
| Disease relevance | Systemic inflammatory response syndrome, sepsis, uveitis, and inflammatory pain [5,6,8]. |
| Research methods | CRISPR knockout/knock-in, RNA-seq, proteomics, flow cytometry, and macrophage infection models [1,2,5]. |
What Is GO:0046696?
In plain terms, the lipopolysaccharide receptor complex is the cell-surface machine that detects LPS, a major component of Gram-negative bacterial outer membranes. According to the Gene Ontology, it is a multiprotein complex containing at least CD14, TLR4, and MD-2, each glycosylated, that functions as an LPS receptor and primes innate immunity against bacterial pathogens. It is annotated as a cellular component (GO:0046696) and is also known as the LPS receptor complex. The complex is not merely a binding site; it is a signal-transducing assembly whose composition and abundance change with infection, inflammation, and host metabolic state [1,5].
Why Is lipopolysaccharide receptor complex Important in Cell Biology?
GO:0046696 is important because it is the primary molecular interface between Gram-negative bacteria and the innate immune system. The complex determines the magnitude and duration of inflammatory signaling, and its dysregulation is linked to systemic inflammatory response syndrome, sepsis tolerance, and tissue-specific inflammation. Because the complex is composed of three genetically separable subunits, it is an ideal subject for CRISPR functional genomics: knockout of TLR4, MD-2, or CD14 can uncouple ligand binding from signal transduction, while point mutations and knock-in reporters can resolve subunit-specific contributions [1,2,5]. Understanding this complex also matters beyond infection, as it is expressed by antigen-presenting cells in immune-privileged sites such as the uvea and by tissue CD14+CD8+ T cells reprogrammed by myeloid cells, linking LPS sensing to adaptive immunity and pain [2,6,8].
• Defines the first step in innate immune recognition of Gram-negative bacteria.
• Controls NF-kB and interferon responses that shape sepsis outcomes [4,5].
• Its expression is altered in systemic inflammatory response syndrome and correlates with LPS tolerance.
• Modulated by host lipid enzymes such as LPCAT2 and by LPS serotype in macrophages.
• Expressed by resident antigen-presenting cells in the human uvea, implicating it in ocular immune privilege.
• Reprogrammed in tissue CD14+CD8+ T cells by myeloid cells and modulated by LPS.
• Intersects with inflammatory caspase-4 and non-canonical inflammasome cytokine cleavage.
• Contributes to mechanisms of pain from urinary tract infection.
• Provides a tractable three-subunit target for CRISPR knockout, point-mutation, and knock-in studies [1,2,5].
• Relevant to type 2 diabetes mellitus through multi-omic causal networks of arsenic-related genes.
What Happens During lipopolysaccharide receptor complex?
LPS recognition and presentation by CD14
In simple terms: CD14 grabs LPS and hands it to the signaling pair.
The lipopolysaccharide receptor complex begins with CD14, a glycosylated co-receptor that binds LPS and presents it to the TLR4/MD-2 pair. CD14 can be membrane-anchored or soluble, and its presence enhances LPS responsiveness. In infected macrophages, expression of the complex is influenced by LPCAT2 and varies with E. coli LPS serotype, indicating that ligand structure and host lipid metabolism modulate this initial recognition step.
LPS binding by MD-2 and TLR4 activation
In simple terms: MD-2 holds LPS, and TLR4 flips the switch.
MD-2 is the direct LPS-binding subunit and associates with the ectodomain of TLR4. Upon LPS binding, TLR4 undergoes dimerization and conformational change, which is the critical activation step of the complex. Structural and functional studies show that TLR4 is the signal-transducing subunit, while MD-2 determines ligand specificity. The complex is glycosylated on all three core proteins, and glycosylation affects trafficking and ligand recognition.
Intracellular signaling and cytokine cleavage
In simple terms: The signal travels inside the cell and can also trigger caspase-4.
Activated TLR4 recruits adaptor proteins and initiates NF-kB and IRF-dependent transcription, leading to pro-inflammatory cytokines. In parallel, intracellular LPS can be sensed by inflammatory caspase-4, which cleaves cytokines and drives non-canonical inflammasome responses. This places the lipopolysaccharide receptor complex at the intersection of surface and cytosolic LPS sensing.
Modulation in inflammation and tolerance
In simple terms: In sepsis, the receptor complex changes its expression and can become tolerant.
In patients with systemic inflammatory response syndrome, expression of CD14, TLR4, and MD-2 is modulated and relates to LPS tolerance. This means the complex is not a fixed unit but a dynamic assembly whose subunit levels change with disease state. Such plasticity has implications for sepsis diagnostics and for designing therapies that target the complex.
Tissue-specific expression and immune reprogramming
In simple terms: The complex appears in specialized tissues and immune cells.
Resident antigen-presenting cells in the human uvea express TLR4 and its associated lipopolysaccharide receptor complex, suggesting a role in ocular immune responses. Tissue CD14+CD8+ T cells can be reprogrammed by myeloid cells and modulated by LPS, linking the complex to adaptive immune cell function. These findings expand the relevance of GO:0046696 beyond classical myeloid cells [2,6].
Key Genes Involved in GO:0046696 lipopolysaccharide receptor complex
The following genes and proteins are the core and associated components of the lipopolysaccharide receptor complex, with roles supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TLR4 | Signal-transducing subunit of the complex; activates NF-kB and IRF pathways upon LPS binding | Primary CRISPR knockout target to uncouple LPS binding from signaling |
| LY96 (MD-2) | Direct LPS-binding co-receptor that associates with TLR4 ectodomain | Point-mutation and knock-in studies to map ligand specificity |
| CD14 | Glycosylated co-receptor that presents LPS to TLR4/MD-2 | Knockout and overexpression models to test LPS sensitivity |
| LPCAT2 | Lipid enzyme that influences gene expression of the lipopolysaccharide receptor complex in infected macrophages | Host-factor knockout to study serotype-dependent receptor regulation |
| CASP4 | Inflammatory caspase that cleaves cytokines downstream of intracellular LPS sensing | Knockout models to separate canonical and non-canonical LPS responses |
| MYD88 | Adaptor protein in TLR4 signaling (canonical pathway) | Knockout to block MyD88-dependent cytokine induction |
| TICAM1 (TRIF) | Adaptor protein in TLR4 signaling (TRIF-dependent pathway) | Knockout to isolate TRIF-dependent interferon responses |
| NFKB1 | Transcription factor activated downstream of the complex | Reporter and knockout models for NF-kB readout |
| IRF3 | Transcription factor activated downstream of TLR4 | Knockout to measure interferon responses |
| LY96 | Alternative symbol for MD-2, the LPS-binding subunit | Used interchangeably in CRISPR design |
| CD8A | Marker of tissue CD14+CD8+ T cells modulated by LPS | Lineage-tracing and knockout in T cell studies |
| ITGAM (CD11b) | Myeloid marker associated with cells that reprogram CD14+CD8+ T cells | Flow cytometry and knockout in myeloid-T cell co-culture |
| HLA-DRA | Antigen-presenting molecule in uveal resident cells expressing the complex | Knock-in reporters for antigen presentation studies |
| TRPV1 | Nociceptor channel implicated in infection-associated pain | Knockout to test pain pathways downstream of LPS sensing |
| INS | Diabetes-related gene in multi-omic networks involving arsenic-related genes | Overexpression and knockout in metabolic models |
| GCG | Glucagon gene in type 2 diabetes multi-omic networks | Knockout to study metabolic crosstalk |
| SLC30A8 | Zinc transporter associated with type 2 diabetes risk | Point-mutation models for functional genetics |
| TNF | Pro-inflammatory cytokine induced downstream of the complex | Reporter and knockout models for inflammation readout |
How Is lipopolysaccharide receptor complex Regulated?
The lipopolysaccharide receptor complex is regulated at multiple levels. Transcriptionally, expression of CD14, TLR4, and MD-2 is modulated in systemic inflammatory response syndrome, and this modulation correlates with LPS tolerance. Post-transcriptionally, host lipid enzymes such as LPCAT2 influence the gene expression of the complex in infected macrophages, and the effect depends on the E. coli LPS serotype. At the protein level, glycosylation of all three core subunits affects assembly and ligand recognition. Signaling output is further regulated by adaptor choice (MyD88 versus TRIF) and by negative feedback loops that prevent excessive inflammation. In tissue contexts, myeloid cells can reprogram CD14+CD8+ T cells, adding a cellular layer of regulation. Finally, intracellular LPS sensing by caspase-4 provides a parallel regulatory node that can amplify or diversify cytokine cleavage.
lipopolysaccharide receptor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TLR4 | Systemic inflammatory response syndrome and LPS tolerance | Knockout macrophages and patient-derived cells |
| CD14 | Sepsis and innate immune hyperactivation | Overexpression and knockout in monocytic cell lines |
| LY96 (MD-2) | LPS responsiveness and tolerance | Point-mutation knock-in to alter ligand binding |
| LPCAT2 | Serotype-dependent regulation of the complex in infected macrophages | Knockout RAW264.7 macrophages infected with E. coli |
| CASP4 | Non-canonical inflammasome and cytokine cleavage | Knockout and reconstitution in epithelial and myeloid cells |
Sepsis and systemic inflammatory response syndrome
The lipopolysaccharide receptor complex is directly implicated in systemic inflammatory response syndrome, where expression of CD14, TLR4, and MD-2 is modulated and relates to LPS tolerance. Because the complex initiates cytokine production, its activity level can determine whether LPS exposure leads to protective immunity or pathological inflammation [4,5]. Experimental models using knockout macrophages and patient-derived cells can test whether individual subunits drive tolerance or hyperinflammation [1,5].
Ocular inflammation and immune privilege
Resident antigen-presenting cells in the human uvea express TLR4 and its associated lipopolysaccharide receptor complex, suggesting that LPS sensing in the eye may contribute to uveitis and to the balance of immune privilege. This makes the complex a candidate target for understanding ocular inflammatory disease and for designing locally acting immunomodulators.
Infection-associated pain
Mechanisms of pain from urinary tract infection involve innate immune sensing pathways, and the lipopolysaccharide receptor complex is part of the LPS recognition machinery that can drive nociceptor activation. Studying this complex in infection models may reveal how bacterial products trigger pain and how to intervene without compromising host defense.
Metabolic and inflammatory crosstalk in type 2 diabetes
Multi-omic analyses of arsenic-related genes in type 2 diabetes mellitus have identified causal networks that include inflammatory and metabolic genes. Although the lipopolysaccharide receptor complex is not the primary focus of that study, chronic low-grade inflammation driven by LPS sensing is a plausible link between environmental exposure and metabolic disease. This highlights the need for careful causal dissection using CRISPR models.
From lipopolysaccharide receptor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TLR4 signaling drive LPS-induced cytokine production? | TLR4 knockout macrophage cell line |
| Does MD-2 ligand specificity depend on a single residue? | MD-2 point-mutation knock-in |
| Can CD14 overexpression sensitize cells to low-dose LPS? | CD14 overexpression cell model |
| How does LPCAT2 loss alter receptor complex gene expression? | LPCAT2 knockout in RAW264.7 macrophages |
| Do tissue CD14+CD8+ T cells require myeloid reprogramming for LPS response? | Co-culture with myeloid cells and CD14 knockout T cells |
| Does caspase-4 mediate non-canonical LPS cytokine cleavage? | CASP4 knockout with intracellular LPS challenge |
How to Study the lipopolysaccharide receptor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcript levels of CD14, TLR4, MD-2 and pathway genes | Serotype-dependent regulation in macrophages |
| qPCR | Targeted gene expression of the receptor complex | Validation of knockout and overexpression models |
| Proteomics / mass spectrometry | Protein abundance and glycosylation of complex subunits | Post-translational regulation studies |
| Flow cytometry | Surface expression of CD14, TLR4, MD-2 on immune cells | Myeloid and T cell reprogramming studies |
| Immunofluorescence imaging | Tissue localization of the complex | Uveal antigen-presenting cell studies |
| Cytokine ELISA | Downstream TNF and IL-6 production | LPS stimulation assays |
| Caspase-4 cleavage assay | Non-canonical inflammasome activity | Intracellular LPS sensing studies |
| CRISPR knockout screening | Causal contribution of each subunit and host factor [1,2,5] | Functional genomics of LPS response [1,2,5] |
Transcriptomic profiling of the receptor complex
RNA-seq and targeted qPCR can quantify CD14, TLR4, and MD-2 expression across conditions. In infected RAW264.7 macrophages, LPCAT2 knockout and different E. coli LPS serotypes alter the gene expression of the lipopolysaccharide receptor complex, demonstrating the value of transcriptomic readouts. Such experiments require careful normalization and biological replicates to detect serotype-specific effects.
Proteomic and glycosylation analysis
Because all three core proteins of the complex are glycosylated, mass spectrometry-based proteomics and lectin blots can resolve subunit abundance and glycoform heterogeneity. These methods complement transcriptomics by capturing post-translational regulation that affects assembly and ligand recognition.
Flow cytometry and imaging of immune cells
Flow cytometry can detect surface CD14, TLR4, and MD-2 on myeloid cells and on tissue CD14+CD8+ T cells reprogrammed by myeloid cells. Imaging of uveal resident antigen-presenting cells has localized the complex in situ, providing spatial context for its function. These approaches are essential for linking expression to cell identity and tissue location [2,6].
Functional assays for LPS response and cytokine cleavage
LPS stimulation assays with cytokine ELISAs measure downstream output of the complex, while caspase-4 cleavage assays detect non-canonical inflammasome activity [3,4]. Combining these readouts with CRISPR perturbations allows causal assignment of each subunit to specific signaling branches [3,4].
How CRISPR Can Be Used to Study GO:0046696 lipopolysaccharide receptor complex
Knockout
CRISPR knockout of TLR4, LY96 (MD-2), or CD14 in macrophage and monocytic cell lines abolishes or reduces LPS responsiveness, allowing researchers to assign signaling roles to each subunit. Knockout of host factors such as LPCAT2 can reveal how lipid metabolism influences the gene expression of the lipopolysaccharide receptor complex in infected macrophages. Knockout of CASP4 separates non-canonical inflammasome cytokine cleavage from canonical TLR4 signaling.
Point Mutation
Point mutations in LY96 (MD-2) or TLR4 can be introduced to test ligand-binding residues and dimerization interfaces without deleting the entire protein. Such models are valuable for distinguishing loss-of-binding from loss-of-signaling phenotypes. In disease-relevant genes identified by multi-omic networks, point mutations can test causal variants.
Knock-in
Knock-in of fluorescent or epitope tags at endogenous CD14, TLR4, or MD-2 loci enables live-cell imaging and proteomic pull-down of the intact complex. Knock-in reporters for NF-kB or interferon response elements can quantify downstream activation in real time. Tissue-specific knock-in can model expression in immune-privileged sites such as the uvea.
Overexpression
Overexpression of CD14, TLR4, or MD-2 can sensitize cells to low-dose LPS and amplify signaling for biochemical assays. Overexpression of LPCAT2 or its mutants can test how lipid remodeling affects receptor complex gene expression. Overexpression models are also useful for studying CD14+CD8+ T cell reprogramming by myeloid cells.
How EDITGENE Supports lipopolysaccharide receptor complex Research
Researchers studying lipopolysaccharide receptor complex-related genes often need to determine whether a candidate gene is causally involved in LPS sensing, inflammation, or tissue-specific immune regulation. EDITGENE provides CRISPR-based cell model engineering and screening services that allow precise, reproducible interrogation of GO:0046696 components and their regulators.
Contact EDITGENE today to design your custom CRISPR model for lipopolysaccharide receptor complex research.
Frequently Asked Questions About lipopolysaccharide receptor complex
What is the lipopolysaccharide receptor complex?
It is a glycosylated multiprotein complex of CD14, TLR4, and MD-2 that binds bacterial LPS and primes innate immunity, annotated as GO:0046696.
What genes are involved in the lipopolysaccharide receptor complex?
The core genes are TLR4, LY96 (MD-2), and CD14; associated regulators include LPCAT2, MYD88, TICAM1, and CASP4 [1,3,4].
What is GO:0046696?
GO:0046696 is the Gene Ontology identifier for the cellular component lipopolysaccharide receptor complex, also known as the LPS receptor complex.
How is the lipopolysaccharide receptor complex regulated?
Its expression is modulated in systemic inflammatory response syndrome and by host factors such as LPCAT2, with effects depending on LPS serotype [1,5].
Which diseases involve the lipopolysaccharide receptor complex?
It is linked to systemic inflammatory response syndrome, sepsis tolerance, uveitis, infection-associated pain, and inflammatory crosstalk in metabolic disease [5,6,7,8].
How can CRISPR be used to study the lipopolysaccharide receptor complex?
CRISPR knockout, point mutation, knock-in, and overexpression can assign causal roles to TLR4, MD-2, CD14, and their regulators in LPS response assays [1,2,3,4].
What cell models are best for studying LPS receptor complex function?
Macrophage lines such as RAW264.7, monocytic cell lines, and primary myeloid cells are commonly used, with infection or LPS stimulation readouts [1,5].
Does the lipopolysaccharide receptor complex exist in immune-privileged tissues?
Yes, resident antigen-presenting cells in the human uvea express TLR4 and its associated complex.
What is the role of MD-2 in the lipopolysaccharide receptor complex?
MD-2 is the direct LPS-binding subunit that associates with TLR4 and determines ligand specificity.
How does caspase-4 relate to the lipopolysaccharide receptor complex?
Caspase-4 senses intracellular LPS and cleaves cytokines, providing a non-canonical branch that intersects with surface LPS sensing.
Conclusion
The lipopolysaccharide receptor complex (GO:0046696) is a three-subunit, glycosylated cellular machine that converts bacterial LPS recognition into innate immune signaling. Its expression and composition are dynamically regulated in infection and inflammation, with host factors such as LPCAT2 and ligand serotype shaping its output [1,5]. The complex also appears in specialized tissues and immune cell populations, broadening its biological reach [2,6]. For researchers, the complex offers a genetically tractable system: CRISPR knockout, point mutation, knock-in, and overexpression models can dissect the contribution of each subunit and its regulators to LPS responses and disease [1,2,3,4,5]. Combining these models with transcriptomics, proteomics, and functional assays will continue to clarify how GO:0046696 drives protective immunity versus pathological inflammation [1,3,4,5].
References
- 1. Poloamina VI et al.. 2024. Lysophosphatidylcholine Acetyltransferase 2 (LPCAT2) Influences the Gene Expression of the Lipopolysaccharide Receptor Complex in Infected RAW264.7 Macrophages, Depending on the E. coli Lipopolysaccharide Serotype.. Biology (Basel) 13(5) PMID: 38785798
- 2. Pallett LJ et al.. 2023. Tissue CD14(+)CD8(+) T cells reprogrammed by myeloid cells and modulated by LPS.. Nature 614(7947):334-342 PMID: 36697826
- 3. Devant P et al.. 2023. Structural insights into cytokine cleavage by inflammatory caspase-4.. Nature 624(7991):451-459 PMID: 37993712
- 4. Pålsson-McDermott EM et al.. 2004. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4.. Immunology 113(2):153-62 PMID: 15379975
- 5. Calvano JE et al.. 2003. Modulation of the lipopolysaccharide receptor complex (CD14, TLR4, MD-2) and toll-like receptor 2 in systemic inflammatory response syndrome-positive patients with and without infection: relationship to tolerance.. Shock 20(5):415-9 PMID: 14560104
- 6. Chang JH et al.. 2004. Expression of toll-like receptor 4 and its associated lipopolysaccharide receptor complex by resident antigen-presenting cells in the human uvea.. Invest Ophthalmol Vis Sci 45(6):1871-8 PMID: 15161852
- 7. Yang H et al.. 2025. Multi-omic insight into the causal networks of arsenic-related genes in the pathogenesis of type 2 diabetes mellitus.. Ecotoxicol Environ Saf 305:119195 PMID: 41072314
- 8. Rosen JM et al.. 2014. Mechanisms of pain from urinary tract infection.. Int J Urol 21 Suppl 1(0 1):26-32 PMID: 24807489
